If the theoretical therapeutic benefit of pentoxifylline for COVID‐19 based on its anti‐Tumor Necrosis Factor effect is clinically demonstrable, it may prove to be an inexpensive, and readily available, treatment strategy to target harmful cytokine excess in this disease. The gene discussed is TNF; the disease is COVID-19.